Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching
BioSpace
Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.
pharminent
May 13, 2026 (Last updated: May 19, 2026)
BioSpace
Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.
